{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:08:27Z","timestamp":1788246507933,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"German Ministry of Health","award":["ZMV I1-2517 FSB 413"],"award-info":[{"award-number":["ZMV I1-2517 FSB 413"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe flu-like symptoms. The acute symptoms disappear after 1 week, but chronic arthralgia can persist for years. In this study, humoral immune responses in CHIKV-infected patients and vaccinees were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Alphavirus neutralization activity was analyzed with pseudotyped lentiviral vectors, and antibody epitope mapping was performed with a peptide array.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The greatest CHIKV neutralization activity was observed 60\u201392 days after onset of symptoms. The amount of CHIKV-specific antibodies and their binding avidity and cross-reactivity with other alphaviruses increased over time. Chikungunya virus and o\u2019nyong-nyong virus (ONNV) were both neutralized to a similar extent. Linear antibody binding epitopes were mainly found in E2 domain B and the acid-sensitive regions (ASRs). In addition, serum samples from healthy volunteers vaccinated with a measles-vectored chikungunya vaccine candidate, MV-CHIK, were analyzed. Neutralization activity in the samples from the vaccine cohort was 2- to 6-fold lower than in samples from CHIKV-infected patients. In contrast to infection, vaccination only induced cross-neutralization with ONNV, and the E2 ASR1 was the major antibody target.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data could assist vaccine design and enable the identification of correlates of protection necessary for vaccine efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz658","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T20:09:21Z","timestamp":1576094961000},"page":"1713-1723","source":"Crossref","is-referenced-by-count":31,"title":["Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine"],"prefix":"10.1093","volume":"221","author":[{"given":"Lisa","family":"Henss","sequence":"first","affiliation":[{"name":"Paul-Ehrlich-Institut, Department of Virology, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Yue","sequence":"first","affiliation":[{"name":"Paul-Ehrlich-Institut, Department of Virology, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Von Rhein","sequence":"first","affiliation":[{"name":"Paul-Ehrlich-Institut, Department of Virology, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tschismarov","sequence":"first","affiliation":[{"name":"Themis Bioscience GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Laura","family":"Lewis-Ximenez","sequence":"first","affiliation":[{"name":"Instituto Oswaldo Cruz, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"D\u00f6lle","sequence":"first","affiliation":[{"name":"Independent Researcher, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A","family":"Baylis","sequence":"first","affiliation":[{"name":"Paul-Ehrlich-Institut, Department of Virology, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S","family":"Schnierle","sequence":"first","affiliation":[{"name":"Paul-Ehrlich-Institut, Department of Virology, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"2020042708360131000_CIT0001","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020042708360131000_CIT0002","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1586\/14760584.7.7.889","article-title":"Clinical development of MVA-based therapeutic cancer vaccines","volume":"7","author":"Acres","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"2020042708360131000_CIT0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature09555","article-title":"Glycoprotein organization of chikungunya virus particles revealed by x-ray crystallography","volume":"468","author":"Voss","year":"2010","journal-title":"Nature"},{"key":"2020042708360131000_CIT0004","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nature09546","article-title":"Structural changes of envelope proteins during alphavirus fusion","volume":"468","author":"Li","year":"2010","journal-title":"Nature"},{"key":"2020042708360131000_CIT0005","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J Immunol"},{"key":"2020042708360131000_CIT0006","doi-asserted-by":"crossref","first-page":"e0005637","DOI":"10.1371\/journal.pntd.0005637","article-title":"Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques","volume":"11","author":"Broeckel","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2020042708360131000_CIT0007","doi-asserted-by":"crossref","first-page":"eaah3438","DOI":"10.1126\/scitranslmed.aah3438","article-title":"Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis","volume":"9","author":"Miner","year":"2017","journal-title":"Sci Transl Med"},{"key":"2020042708360131000_CIT0008","doi-asserted-by":"crossref","first-page":"e1003312","DOI":"10.1371\/journal.ppat.1003312","article-title":"Development of a highly protective combination monoclonal antibody therapy against chikungunya virus","volume":"9","author":"Pal","year":"2013","journal-title":"PLoS Pathog"},{"key":"2020042708360131000_CIT0009","doi-asserted-by":"crossref","first-page":"e2423","DOI":"10.1371\/journal.pntd.0002423","article-title":"A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease","volume":"7","author":"Selvarajah","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020042708360131000_CIT0010","doi-asserted-by":"crossref","first-page":"eaav5062","DOI":"10.1126\/sciimmunol.aav5062","article-title":"Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-Fc\u03b3R interaction on monocytes","volume":"4","author":"Fox","year":"2019","journal-title":"Sci Immunol"},{"key":"2020042708360131000_CIT0011","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.celrep.2015.11.043","article-title":"Neutralizing monoclonal antibodies block chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis","volume":"13","author":"Jin","year":"2015","journal-title":"Cell Rep"},{"key":"2020042708360131000_CIT0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","article-title":"Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus","volume":"18","author":"Smith","year":"2015","journal-title":"Cell Host Microbe"},{"key":"2020042708360131000_CIT0013","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"2020042708360131000_CIT0014","doi-asserted-by":"crossref","first-page":"pii:E82","DOI":"10.3390\/v11010082","article-title":"Establishment of an alphavirus-specific neutralization assay to distinguish infections with different members of the semliki forest complex","volume":"11","author":"Henss","year":"2019","journal-title":"Viruses"},{"key":"2020042708360131000_CIT0015","doi-asserted-by":"crossref","first-page":"e0171989","DOI":"10.1371\/journal.pone.0171989","article-title":"The neutralizing role of IgM during early chikungunya virus infection","volume":"12","author":"Chua","year":"2017","journal-title":"PLoS One"},{"key":"2020042708360131000_CIT0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0923-2516(96)80591-7","article-title":"Antigenic relationship between chikungunya virus strains and o\u2019nyong nyong virus using monoclonal antibodies","volume":"146","author":"Blackburn","year":"1995","journal-title":"Res Virol"},{"key":"2020042708360131000_CIT0017","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrmicro2368","article-title":"Biology and pathogenesis of chikungunya virus","volume":"8","author":"Schwartz","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"2020042708360131000_CIT0018","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2018.10.033","article-title":"Defining","volume":"37","author":"Milligan","year":"2019","journal-title":"Vaccine"},{"key":"2020042708360131000_CIT0019","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/infdis\/jiz202","article-title":"Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman primates","volume":"220","author":"Rossi","year":"2019","journal-title":"J Infect Dis"},{"key":"2020042708360131000_CIT0020","doi-asserted-by":"crossref","first-page":"e0003764","DOI":"10.1371\/journal.pntd.0003764","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2020042708360131000_CIT0021","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4269\/ajtmh.18-0756","article-title":"Neutralizing antibodies from convalescent chikungunya virus patients can cross-neutralize mayaro and una viruses","volume":"100","author":"Martins","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2020042708360131000_CIT0022","doi-asserted-by":"crossref","first-page":"e00003","DOI":"10.1128\/mSphere.00003-18","article-title":"Human antibody responses to emerging mayaro virus and cocirculating alphavirus infections examined by using structural proteins from nine new and old world lineages","volume":"3","author":"Smith","year":"2018","journal-title":"mSphere"},{"key":"2020042708360131000_CIT0023","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.vaccine.2012.04.099","article-title":"Cross-protective immunity against o\u2019nyong-nyong virus afforded by a novel recombinant chikungunya vaccine","volume":"30","author":"Partidos","year":"2012","journal-title":"Vaccine"},{"key":"2020042708360131000_CIT0024","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3201\/eid2012.141269","article-title":"Evaluation of commercially available serologic diagnostic tests for chikungunya virus","volume":"20","author":"Prat","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2020042708360131000_CIT0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med"},{"key":"2020042708360131000_CIT0026","doi-asserted-by":"crossref","first-page":"13005","DOI":"10.1128\/JVI.01780-12","article-title":"Longitudinal analysis of the human antibody response to chikungunya virus infection: implications for serodiagnosis and vaccine development","volume":"86","author":"Kam","year":"2012","journal-title":"J Virol"},{"key":"2020042708360131000_CIT0027","doi-asserted-by":"crossref","first-page":"e3445","DOI":"10.1371\/journal.pntd.0003445","article-title":"Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients","volume":"9","author":"Kam","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2020042708360131000_CIT0028","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J Infect Dis"},{"key":"2020042708360131000_CIT0029","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cell.2015.10.050","article-title":"Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress","volume":"163","author":"Fox","year":"2015","journal-title":"Cell"},{"key":"2020042708360131000_CIT0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.virol.2007.09.028","article-title":"Production and characterization of mouse monoclonal antibodies reactive to chikungunya envelope E2 glycoprotein","volume":"371","author":"Br\u00e9hin","year":"2008","journal-title":"Virology"},{"key":"2020042708360131000_CIT0031","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.cell.2015.11.006","article-title":"Potent antibody protection against an emerging alphavirus threat","volume":"163","author":"Kielian","year":"2015","journal-title":"Cell"},{"key":"2020042708360131000_CIT0032","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1128\/JVI.01926-14","article-title":"Prime-boost immunization strategies against chikungunya virus","volume":"88","author":"Halleng\u00e4rd","year":"2014","journal-title":"J Virol"},{"key":"2020042708360131000_CIT0033","doi-asserted-by":"crossref","first-page":"e0003684","DOI":"10.1371\/journal.pntd.0003684","article-title":"A small antigenic determinant of the chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice","volume":"9","author":"Weber","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2020042708360131000_CIT0034","doi-asserted-by":"crossref","first-page":"e95647","DOI":"10.1371\/journal.pone.0095647","article-title":"Unique epitopes recognized by antibodies induced in chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development","volume":"9","author":"Kam","year":"2014","journal-title":"PLoS One"},{"key":"2020042708360131000_CIT0035","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.celrep.2018.11.067","article-title":"Cryo-EM structures of eastern equine encephalitis virus reveal mechanisms of virus disassembly and antibody neutralization","volume":"25","author":"Hasan","year":"2018","journal-title":"Cell Reports"},{"key":"2020042708360131000_CIT0036","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0166-0934(87)90059-0","article-title":"Nonspecific binding of immunoglobulins to coat proteins of certain plant viruses in immunoblots and indirect ELISA","volume":"15","author":"Dietzgen","year":"1987","journal-title":"J Virol Methods"},{"key":"2020042708360131000_CIT0037","doi-asserted-by":"crossref","first-page":"14364","DOI":"10.1128\/JVI.01943-14","article-title":"Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy","volume":"88","author":"Fong","year":"2014","journal-title":"J Virol"},{"key":"2020042708360131000_CIT0038","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.cell.2019.04.006","article-title":"Cryo-EM structure of chikungunya virus in complex with the Mxra8 receptor","volume":"177","author":"Basore","year":"2019","journal-title":"Cell"},{"key":"2020042708360131000_CIT0039","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.cell.2019.04.008","article-title":"Molecular basis of arthritogenic alphavirus receptor MXRA8 binding to chikungunya virus envelope protein","volume":"177","author":"Song","year":"2019","journal-title":"Cell"},{"key":"2020042708360131000_CIT0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/femspd\/ftu002","article-title":"Anti-tick-borne encephalitis (TBE) virus neutralizing antibodies dynamics in natural infections versus vaccination","volume":"73","author":"Remoli","year":"2015","journal-title":"Pathog Dis"},{"key":"2020042708360131000_CIT0041","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1128\/JCM.40.5.1733-1738.2002","article-title":"Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups","volume":"40","author":"Itoh","year":"2002","journal-title":"J Clin Microbiol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz658\/31712867\/jiz658.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/10\/1713\/33131326\/jiz658.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/10\/1713\/33131326\/jiz658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:51:03Z","timestamp":1588009863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/10\/1713\/5673548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2020,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz658","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,15]]},"published":{"date-parts":[[2019,12,12]]}}}